Profound Medical Corp.
PROF
Positions held
Your positionsPROF isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $257.97M | Enterprise value | $221.55M | Trailing P/E | — | Forward P/E | -12.01 |
| PEG | — | Price / book | 5.18 | Beta | 0.56 | Dividend yield | 0.00% |
| Revenue growth | 12.3% | Earnings growth | — | Gross margin | 71.8% | Operating margin | -4.5% |
| Profit margin | -1.7% | ROE | -73.5% | ROA | -39.5% | Debt / equity | 0.15 |
| Current ratio | 6.46 | Free cash flow | -$24.82M | Analyst recommendation | strong_buy | Mean target | $11.14 |
| 52w high | $8.95 | 52w low | $4.80 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $2.5M | $5.3M | $6.0M | $5.3M | $2.2M |
| Op margin | -445.7% | -150.3% | -123.3% | -168.5% | -624.4% |
| Net income | -$9.5M | -$7.1M | -$8.2M | -$8.0M | -$15.7M |
| Gross margin | 78.4% | 71.8% | 66.8% | 74.3% | 73.2% |
| Gross profit | $1.9M | $3.8M | $4.0M | $3.9M | $1.6M |
| Operating income | -$11.1M | -$8.0M | -$7.4M | -$8.9M | -$13.8M |
- Revenue -53% vs prior quarter ($2.5M vs $5.3M).
- Gross margin 78.4% (was 71.8% prior quarter).
- Operating margin compressed to -445.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $16.1M | $10.7M | $7.2M | $6.7M | — |
| Op margin | -256.3% | -309.6% | -398.0% | -443.1% | — |
| Net income | -$42.6M | -$27.8M | -$28.3M | -$28.7M | — |
| Gross margin | 70.8% | 65.9% | 59.9% | 45.2% | — |
| Gross profit | $11.4M | $7.0M | $4.3M | $3.0M | — |
| Operating income | -$41.3M | -$33.1M | -$28.7M | -$29.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Profound Medical and Telix Pharmaceuticals Partner to Advance Prostate Cancer Imaging and Treatment Education
2026-10-09 · Profound Medical, Telix Pharmaceuticals Enter Prostate-Care Education Agreement
2026-10-09 · Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
2026-10-09 · Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
2026-10-07 · Profound Medical Reports Preliminary Q3 Revenue Above Street View; Shares Rise After-Hours
2026-10-07 · Profound Medical Up 14% After Hours as It Expects Record Third-Quarter Revenue
2026-10-07 · Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
2026-10-04 · 3 Canadian AI Stocks With Up To 58% Earnings Growth
2026-09-25 · 3 Canadian AI Healthcare Stocks With Market Caps Up To $296 Million
2026-09-06 · Profound Medical Stock And 2 Canadian AI Healthcare Stocks To Watch
2026-09-03 · Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference
2026-09-01 · Profound Medical Appoints Richard Fabian as President
Price (daily)
Full chart · RSI · MACD · patterns